NCT06900517

The Efficacy of Salvia Officinalis Gel in the Treatment of Periodontitis CLINICAL TRIAL

The Efficacy of Salvia Officinalis Gel in the Treatment of Periodontitis by Monitoring Gingival Crevicular Fluid Volume and Interleukin 17 Concentration

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 23 (estimated)
• Sponsor: University of Baghdad · Academic / Other
• Sex: All
• Age: 25 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

From each participant, two sites of periodontal pockets ( ≥ 5 mm ) were selected and randomly allocated to either the test site (treated with scaling and RSD with S. officinalis gel) or the control site (treated with scaling and RSD alone).

Detailed description

Background: Phytotherapy relies on the use of extracts derived from plants in pharmaceutical form. Herbal products have been effective in reducing periodontal diseases, as stated by many studies. Gingival crevicular fluid volume and concentrations of certain cytokines are precise and objective parameters in evaluating periodontitis treatment. Aim of the study: Assessment of local application of Salvia officinalis (S. officinalis) gel as an adjunctive to scaling and root surface debridement (RSD) in the management of periodontitis. Methods: A randomized clinical trial of split-mouth design for twenty-three subjects with periodontitis was assessed in this study. From each participant, two sites of periodontal pockets ( ≥ 5 mm ) were selected and randomly allocated to either the test site (treated with scaling and RSD with S. officinalis gel) or the control site (treated with scaling and RSD alone). A highly sensitive enzyme-linked immunosorbent assay (ELISA) was used to determine the concentration of interleukin 17 (IL-17) in gingival crevicular fluid (GCF).

Conditions

• Periodontal Pocket

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Salvia officinalis Gel	From each participant, two sites of periodontal pockets ( ≥ 5 mm ) were selected and randomly allocated to either the test site (treated with scaling and RSD with S. officinalis gel) or the control site (treated with scaling and RSD alone).

Timeline

• Start date: 2025-05-01
• Primary completion: 2025-10-01
• Completion: 2025-11-01
• First posted: 2025-03-28
• Last updated: 2025-03-28